Premium
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19
Author(s) -
Zhang Chi,
Wu Zhao,
Li JiaWen,
Tan Kangan,
Yang Wanna,
Zhao Hong,
Wang GuiQiang
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26634
Subject(s) - pulmonary fibrosis , medicine , fibrosis , pirfenidone , nintedanib , idiopathic pulmonary fibrosis , covid-19 , lung , disease , infectious disease (medical specialty)
Since December 2019, coronavirus disease (COVID‐19) has rapidly swept the world. So far, more than 30 million people have been infected and nearly one million have died. Although the world is still in the stage of COVID‐19 pandemic, the treatment of new cases and critically ill patients is the focus of the current work. However, COVID‐19 patients lead to pulmonary fibrosis, such a serious threat to the prognosis of complications were also worthy of our attention. First of all, we proposed the possible mechanism of pulmonary fibrosis caused by SARS‐CoV‐2, based on the published data of COVID‐19 ((i) Direct evidence: pulmonary fibrosis was found in autopsy and pulmonary puncture pathology. (ii) Indirect evidence: increased levels of fibrosis‐related cytokines[transforming growth factor [TGF]‐ β, tumor necrosis factor [TNF]‐ α, interleukin [IL]‐6, etc] in peripheral blood of severe patients.) What is more, we summarized the role of three fibrosis‐related signaling pathways (TGF‐ β signal pathway, WNT signal pathway and YAP/TAZ signal pathway) in pulmonary fibrosis. Finally, we suggested the therapeutic value of two drugs (pirfenidone and nintedanib) for idiopathic pulmonary fibrosis in COVID‐19‐induced pulmonary fibrosis.